AAAAAA

   
Results: 1-9 |
Results: 9
CLINICAL-PHASE-I STUDY WITH ONE-HOUR PACLITAXEL INFUSION
Authors: MROSS K HAUNS B HARING B BAUKNECHT T MEERPOHL HG UNGER C MAIERLENZ H
Citation: K. Mross et al., CLINICAL-PHASE-I STUDY WITH ONE-HOUR PACLITAXEL INFUSION, Annals of oncology, 9(5), 1998, pp. 569-572
CLINICAL AND PHARMACOKINETIC PHASE-I STUDY WITH TAXOL(R) GIVEN AS SHORT 1-HOUR INTRAVENOUS-INFUSION
Authors: MROSS K HARING B HAUNS B MAIERLENZ H BAUKNECHT T MEERPOHL HG DIERGARTEN K UNGER C
Citation: K. Mross et al., CLINICAL AND PHARMACOKINETIC PHASE-I STUDY WITH TAXOL(R) GIVEN AS SHORT 1-HOUR INTRAVENOUS-INFUSION, European journal of cancer, 33, 1997, pp. 1135-1135
PHASE-II STUDY WITH 5-FLUOROURACIL AND GINKGO-BILOBA EXTRACT IN PATIENTS WITH PANCREAS CA
Authors: STAUDER H HARING RB HAUNS B KUHLMANN J MAIERLENZ H MENG G MROSS K UNGER C
Citation: H. Stauder et al., PHASE-II STUDY WITH 5-FLUOROURACIL AND GINKGO-BILOBA EXTRACT IN PATIENTS WITH PANCREAS CA, European journal of cancer, 33, 1997, pp. 1264-1264
PHASE-I STUDY OF PACLITAXEL ADMINISTERED AS A 1-HOUR IN FUSION - TOXICITY AND PHARMACOKINETICS
Authors: MAIERLENZ H HAUNS B HAERING B KOETTING J MROSS K UNGER C BAUKNECHT T DUBOIS A MEERPOHL HG HOLLAENDER N DIERGARTEN K
Citation: H. Maierlenz et al., PHASE-I STUDY OF PACLITAXEL ADMINISTERED AS A 1-HOUR IN FUSION - TOXICITY AND PHARMACOKINETICS, Seminars in oncology, 24(6), 1997, pp. 16-19
EVALUATION OF THE COBAS-CORE-II IMMUNOCHEMISTRY ANALYZER
Authors: KOTTING J HEINEMANN G SALB I MAIERLENZ H
Citation: J. Kotting et al., EVALUATION OF THE COBAS-CORE-II IMMUNOCHEMISTRY ANALYZER, Journal of automatic chemistry, 18(6), 1996, pp. 205-215
EVALUATION OF THE IMMUNOCHEMISTRY ANALYZER COBAS(R) CORE-II - ESTIMATION OF TUMOR-MARKERS AND THYROID-HORMONES IN PATIENTS WITH HIGH MALIGNANT-TUMOR-DISEASES
Authors: KOETTING J SALB I HEINEMANN G MAIERLENZ H
Citation: J. Koetting et al., EVALUATION OF THE IMMUNOCHEMISTRY ANALYZER COBAS(R) CORE-II - ESTIMATION OF TUMOR-MARKERS AND THYROID-HORMONES IN PATIENTS WITH HIGH MALIGNANT-TUMOR-DISEASES, Clinical chemistry, 42(6), 1996, pp. 201-201
ACTIVITY OF CREATINE-KINASE (CK) AND SUBUNIT CK-MB IN PATIENTS WITH DIFFERENT HIGH MALIGNANT-TUMOR DISEASES
Authors: KOETTING J HENNINGER C DREVS A MAIERLENZ H SONNTAG O
Citation: J. Koetting et al., ACTIVITY OF CREATINE-KINASE (CK) AND SUBUNIT CK-MB IN PATIENTS WITH DIFFERENT HIGH MALIGNANT-TUMOR DISEASES, Clinical chemistry, 42(6), 1996, pp. 674-674
GRANISETRON - PHARMACOLOGICAL TOXICOLOGIC AL PROFILE AND CLINICAL-PHARMACOLOGY OF THE NEW51HT(3) ANTAGONIST
Authors: MAIERLENZ H
Citation: H. Maierlenz, GRANISETRON - PHARMACOLOGICAL TOXICOLOGIC AL PROFILE AND CLINICAL-PHARMACOLOGY OF THE NEW51HT(3) ANTAGONIST, Medizinische Klinik, 90, 1995, pp. 5-7
SYMPOSIUM ON QUALITY ASSURANCE AND GOOD CLINICAL-PRACTICE (GCP) IN CANCER DRUG DEVELOPMENT
Authors: KRANICH AL GASTL G MAIERLENZ H NAGEL GA
Citation: Al. Kranich et al., SYMPOSIUM ON QUALITY ASSURANCE AND GOOD CLINICAL-PRACTICE (GCP) IN CANCER DRUG DEVELOPMENT, Journal of cancer research and clinical oncology, 120(10), 1994, pp. 625-627
Risultati: 1-9 |